Pioneering Innovation in Nutrigenetics & Genetic Healthcare
Dr. Daniel Wallerstorfer, an Austrian molecular biologist and biotechnologist, is the founder and CEO of Novogenia GmbH. With over a decade of experience, he has become a leader in genetic testing, personalized dietary supplements, and cosmetic technologies.
During the COVID-19 pandemic, Novogenia played a pivotal role as Austria’s leading SARS-COV-2 testing laboratory. Dr. Wallerstorfer continues to push the boundaries of genetic innovation, guiding Novogenia and its parent company, DARWIN AG, toward new breakthroughs in healthcare.
Key Innovations
- Automated Gene Testing Lab: Advancing efficiency in genetic diagnostics.
- Over 30 Genetic Tests: Offering actionable insights for personalised care.
- Personalised Health Solutions: Tailored dietary supplements and cosmetics.
- Medical Devices: Novel tools for DNA and COVID sample collection.
- DEEP GENOME AI: AI-powered genome interpretation for advanced insights.
Advancing Science and Supporting Global Innovation
Dr. Daniel Wallerstorfer, a specialist in nutrigenetics and lifestyle genetics with an education from the University of Manchester, is the founder and CEO of Novogenia, a leader in gene analysis since 2009. During the COVID-19 pandemic, Novogenia became Austria’s leading SARS-CoV-2 testing laboratory.
Renowned as an expert in his field, Dr. Wallerstorfer has pioneered innovations such as an automated genetic testing laboratory and the DEEP GENOME AI system for genome interpretation, underscoring his commitment to advancing genetic science. His expertise is sought after by numerous companies, and he frequently shares his knowledge through lectures and collaborations in the fields of genetics, lifestyle genetics, and nutrigenetics.
Among the companies Dr. Wallerstorfer works with include:
Scientific Advisor
Scientific Advisor
Scientific Advisor
Chief Scientific Officer
Scientific Advisor
Education
Dr. Daniel Wallerstorfer, born in Austria, is a biotechnologist and molecular biologist who completed a significant part of his higher education in the United Kingdom. He spent his first 14 years in Salzburg before moving to England to attend Ardingly College, located about 50 kilometers south of London. There, he successfully completed his A-Level examinations, laying the groundwork for his academic career in biotechnology. His scientific career took a decisive turn with his studies in Molecular Biology at the University of Manchester, one of Europe’s leading universities in the field of biotechnology. Â
The university is known for its intensive research and practice-oriented teaching, providing Dr. Wallerstorfer with a solid foundation for his later scientific work. After completing his Bachelor of Science (B.Sc.), he further specialized and pursued a doctoral degree in Biotechnology at the same university. In his doctoral studies, Dr. Wallerstorfer focused on optimizing expression systems for recombinant proteins, particularly in the medical context. His emphasis was on RNAi (RNA interference) and epigenetic processes in cells, research that is particularly relevant for developing innovative medical therapies and diagnostic methods. Â
At the age of just 25, he was awarded the Doctor of Philosophy (PhD) degree by the University of Manchester.Â
During his studies, Dr. Wallerstorfer developed a profound interest in human genetics, particularly in the possibilities of preventive genetic diagnostics. This early fascination laid the foundation for his professional career and led him on the successful path he follows today. He is not only an expert in his field but also a lifelong learner, constantly striving to push the boundaries of knowledge in molecular biology and biotechnology.Â
Childhood in Salzburg; schooling at Ardingly College in England
Molecular biology studies at the University of Manchester
Doctoral focus: recombinant proteins and RNAi
Awarded PhD at age 25
